2238 Kaltenbach, Karol - Thomas Jefferson University - Thomas Jefferson University

Karol Kaltenbach, PhD

Contact Dr. Kaltenbach

1233 Locust Street
Suite 401
Philadelphia, PA 19107

(215) 955-4068

Most Recent Peer-reviewed Publications

  1. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study
  2. Do maternal opioids reduce neonatal regional brain volumes: A pilot study
  3. The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations
  4. Response to Wouldes and Woodward: Maternal methadone dose during pregnancy and infant clinical outcome
  5. Induction of pregnant women onto opioid-agonist maintenance medication: An analysis of withdrawal symptoms and study retention
  6. Cigarette smoking in opioid-dependent pregnant women: Neonatal and maternal outcomes
  7. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine
  8. Opioid dependence during pregnancy: Relationships of anxiety and depression symptoms to treatment outcomes
  9. Buprenorphine treatment of opioid-dependent pregnant women: A comprehensive review
  10. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication
  11. Maternal opioid treatment: Human experimental research (mother)-approach, issues and lessons learned
  12. Co-occurring psychiatric symptoms in opioid-dependent women: The prevalence of antenatal and postnatal depression
  13. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine
  14. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates
  15. Fetal assessment before and after dosing with buprenorphine or methadone
  16. Effect of hepatitis C virus status on liver enzyme 0741 s in opioid-dependent pregnant women maintained on opioid-agonist medication
  17. Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy
  18. Neonatal abstinence syndrome
  19. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: Can we assure the safety of the fetus
  20. Methadone and buprenorphine for the management of opioid dependence in pregnancy